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CATEGORY CLIAC  RECOMMENDATION STATUS 
November 2-3, 
2016 
Biosafety CLIAC proposes that the voluntary Laboratory-Associated Incident 
Reporting System (proposed by the CDC Blue Ribbon Panel 
recommendation in 2012) protect the privacy and confidentiality of 
reporting individual(s) and larger entities, e.g. via anonymity. The system 
should borrow from the principles of existing event-reporting systems 
and focus on incidents, near-misses, and mitigation measures that affect 
the safety of laboratory professionals. Finally, it should foster a non-
punitive culture for reporting. 
CLIAC sent a letter (dated November 29, 
2016) to the Secretary, The U.S. 
Department of Health and Human Services 
(HHS), that included this recommendation. 






Autopsy The CLIAC supports the IOM recommendation that Department of 
Health and Human Services (HHS) provide funding for a designated 
subset of health care systems to conduct routine postmortem 
examinations on appropriately defined categories of patient deaths (for 
example, those listed in the College of American Pathologists Guidelines 
for Non-Forensic Autopsies). These funds should be directly linked to 
proposals for data acquisition, including standardization of autopsy 
procedures and reporting (including death-certificates), with the 
expressed goal of understanding the value of autopsies for improving 
individual and health system outcomes. 
CLIAC sent a letter (dated November 29, 
2016) to the Secretary, The U.S. 
Department of Health and Human Services 
(HHS), that included this recommendation. 













CMS should convene a multidisciplinary group* to 
– Generate a report describing a process for health care 
institutions to improve safe communication and follow-up of 
diagnostic test results to providers and/or patients with clear 
guidelines on timelines for communicating those results; and  
– Provide an implementation and evaluation plan for the process. 
Examples of guidance for the report include: 
– The 2015 VHA policy on communicating test results, 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_I
D=3148.  
– A similar project was the CDC’s Core Elements of Hospital 
Antibiotic Stewardship Programs, 
http://www.cdc.gov/getsmart/healthcare/implementation/core-
elements.html.  
*may include, but is not limited to, representatives from CMS, FDA, CDC, 
diagnostic industry representatives, relevant approved accrediting 
organizations, informaticians, human factors engineers, laboratory 
directors/professionals, clinician end-users,  patient/consumer 
representatives, health IT developers/vendors, and other relevant 
professional organizations.  
Recommendation 1b 
CMS should recommend health care institutions create an 
interdisciplinary team comprised of clinical and diagnostic 
health care professionals, health IT, and other 
safety/human factors experts. This team should conduct 
periodic institutional self-assessments to address areas of 
risk and improvement related to safe communication and 
follow-up of diagnostic results. 
Examples of guidance include: 
– Test Results Reporting & Follow-up ONC SAFER Guide, 
https://www.healthit.gov/safer/guide/sg008.   
– Additional guidance could be obtained from the report in 
Recommendation 1a. 
CLIAC sent a letter (dated November 29, 
2016) to the Secretary, The U.S. 
Department of Health and Human Services 
(HHS), that included this recommendation. 






CATEGORY CLIAC  RECOMMENDATION STATUS 




CLIAC requests that the Office of the National Coordinator for Health 
Information Technology (ONC) Standards and Policy Committees each 
include a pathology informatician (pathologist with expertise in clinical 
informatics) as a committee member.  
CLIAC sent a letter (dated May 9, 2016) to 
the Secretary, The U.S. Department of 
Health and Human Services (HHS), that 
included this recommendation. HHS 
response was sent on June 15, 2016. The 









To facilitate wider uptake of standards for laboratory interoperability, 
HHS should endorse and stimulate adoption of an implementation 
guide/s for laboratory results reporting (e.g., The EHR-Lab 
Interoperability and Connectivity Specification (ELINCS) for orders 
available at: http://www.chcf.org/projects/2009/elincs); and successful 
pilots that arise from the S&I framework effort 
(http://wiki.siframework.org/Laboratory+Orders+Interface+Initiative) 
CLIAC sent a letter (dated May 9, 2016) to 
the Secretary, HHS, that included this 
recommendation. HHS response was sent 
on June 15, 2016. The letter and response 







CATEGORY CLIAC  RECOMMENDATION STATUS 
April 13-14,  
2016 
Biosafety CLIAC considers the matter of biosafety in clinical laboratories as an 
urgent unmet national need. We therefore recommend that CDC 
convene a multidisciplinary task force to develop a biosafety strategy for 
clinical laboratories that:   
- Includes stakeholders from all areas of clinical laboratories (including 
professional societies), diagnostic instrumentation industry, other 
relevant Federal agencies, and patient/clinician representatives.  
- Recommends areas requiring further research in clinical laboratory 
safety.   
- Develops tools, templates, and guidelines for risk assessment in all 
areas of the clinical laboratories, both for routine operations and for 
emerging infectious diseases.  
- Publishes interim materials and progress reports broadly, and 
specifically to CLIAC, to inform and to solicit input from the clinical 
laboratory and broader medical communities.   
- Describes cultural, regulatory, measurement, and evaluation 
strategies for goal achievement in biosafety.   
- Develops a framework for implementation of good clinical practices 
that also addresses transparent evaluation and monitoring of 
biosafety practices. 
CDC is addressing this recommendation 





 CDC should review the process by which CLIAC creates, reviews, and 
edits official committee recommendations to allow a public forum for 
shared development and drafting of proposed recommendations prior 
to the meeting to facilitate more effective committee discussion. 
CDC's Committee Management Office and 
General Counsel discussed the 
recommendation process at the April 13-
14, 2016 CLIAC meeting. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
November 18-19, 
2015 
Prenatal Testing  HHS and CDC should support the development of Non-invasive 
prenatal testing (NIPT)-related enduring educational materials 
accessible to patients and health care providers. In order to support 
effective patient care decisions, these materials should include simple 
language and visual graphics to effectively convey information about 
risks, benefits, and limitations of different types of prenatal testing. 
 HHS should require that ordering providers requesting non-invasive 
prenatal screening tests (of cell-free fetal DNA) should perform and 
document a pre-test discussion to inform the patient of risks, benefits, 
and limitations.   
 HHS should recommend labs performing NIPT to disclose information 
regarding test limitations and positive predictive values (likelihood that 
the fetus has a genetic condition) that is directly comparable to 
conventional techniques (e.g., by maternal age) while reporting results 
as well as risk interpretation and appropriate indications for 
confirmatory diagnostic testing.  
CLIAC sent a letter (dated January 4, 2016) 
to the Secretary, HHS, that included this 
recommendation. HHS response was sent 
on March 7, 2016. CLIAC was provided the 
HHS letter and response on April 13, 2016. 









HHS should ensure the following next steps:  
• EHR content display related to laboratory data (including graphs) 
should be standardized such that all CLIA-required test report elements 
are on every laboratory display/graph. 
• National Institute of Standards and Technology (NIST) should create 
use cases for testing transmission and display of laboratory data in the 
pre- and post-implementation stages of EHR use in order to maintain 
semantic interoperability in various laboratory (clinical/anatomic 
pathology) settings. Use cases should start at the laboratory system 
and involve sending data across the interface for display in multiple 
EHRs. This would test the interoperability of comments, units, 
reference ranges, etc. (sometimes the reference ranges in the EHR are 
different than in the laboratory information system). 
• Consider the incorporation of CLIA use cases in next certification 
cycle. 
• The Centers for Medicare & Medicaid Services (CMS) should consider 
identifying activities considered as ‘information blocking’ and place 
multifaceted strategies to discourage such activities. For example, 
incentives could be built for offsetting the current high fees for 
laboratory/EHR interfaces. 
CLIAC sent a letter (dated January 4, 2016) 
to the Secretary, HHS, that included this 
recommendation. HHS response was sent 
on March 7, 2016. CLIAC was provided the 
HHS letter and response on April 13, 2016. 







CATEGORY CLIAC  RECOMMENDATION STATUS 
April 15-16,  
2015 
Safety With regard to emerging infections, HHS should: 
1. Provide oversight that ensures assessment of the safety and 
decontamination of laboratory instrumentation by manufacturers. 
2. Ensure that biosafety training and assessment is required of all CLIA-
certified laboratories, including personnel responsible for the 
preanalytical, analytical, and postanalytical phases of testing. 
3. Ensure oversight, input, and resources into studies evaluating the 
safety of all laboratory practices, instrument testing, etc., so that 
studies are sound, robust, evidence-based, and applicable. 
4. Develop a process for investigating and reporting laboratory 
acquired infections. 
CLIAC sent a letter (dated May 6, 2015) to 
the Secretary, HHS, that included this 
recommendation. HHS response was sent 
to CLIAC on August 5, 2015. The letter and 





April 15-16,  
2015 
EHR HHS should convene a multidisciplinary stakeholder group that: 
 Includes, but is not limited to, representatives from  ONC, CMS, FDA, 
CDC, industry representatives, health IT developers/vendors, all CLIA 
approved accrediting organizations, informaticians, lab 
directors/professionals, provider end-users,  patient/consumer 
representatives, & other relevant professional organizations 
 Proposes a framework for achieving safe & effective lab 
interoperability  (both system and patient facing) that encourages 
innovation and defines how to operationalize interoperability (and 
related deliverables) with detailed use cases 
 Provides both short term next steps and long term goals with 
definable measurable actions and outline who is responsible for 
these actions 
 Puts into place robust measurement and evaluation strategies for 
goal achievement. 
CLIAC sent a letter (dated May 6, 2015) to 
the Secretary, HHS, that included this 
recommendation. HHS response was sent 
on July 24, 2015. CLIAC was provided the 
HHS letter and response on November 5, 








Histocompatibility CMS should explore: 
a. Regulatory changes or guidance(s) that would allow virtual 
crossmatching to replace physical crossmatching as a pre-requisite 
for organ transplant;  
b. Appropriate criteria and decision algorithms, based on the Virtual 
Crossmatch Workgroup input provided to CLIAC, under which virtual 
crossmatching would be an appropriate substitute for physical 
crossmatching. The determination of appropriate criteria and 
decision algorithms should involve a process that includes an open 
comment period.    




CATEGORY CLIAC  RECOMMENDATION STATUS 
November 5-6, 
2014 
Waived Testing CMS should revisit the A19 request to open up the CLIA law to allow 
changes to the waived testing requirements and provide a description of 
the details of the A19 request at the next CLIAC meeting. 
CMS reported on this during April 15-16, 
2015 CLIAC meeting.   
November 5-6, 
2014 
Waived Testing HHS should facilitate the development of a non-punitive and non-
regulatory self-assessment checklist-type tool and recommend it for 
biennial use by all Certificate of Waiver testing sites. It could also be 
used prior to or at the time a site first applies for a CLIA Certificate. 
 Items on the checklist should include recommended practices based 
on the “Ready? Set? Test!” booklet and should address known 
problem areas of importance (e.g., off-label use of waived tests). 
 The checklist could also assess whether the Certificate of Waiver site 
reports test system performance problems to the FDA. 
 Certificate of Waiver testing sites should be encouraged to keep 
copies of their completed assessments on file to be validated during 
CMS site visits and/or the assessments could be reported to CMS 
through an online portal. 
Self-assessment checklist based on Ready? 
Set? Test! recommended practices was 
completed and is available at 
http://wwwn.cdc.gov/clia/Resources/Wai
vedTests/default.aspx.  
August 21-22,  
2013 
Cytology Clinical Laboratory Improvement Advisory Committee (CLIAC) endorses 
use of College of American Pathologists (CAP) Guidelines as a model for 
validation of whole slide imaging systems for clinical use. 
No action required. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
August 29-30,  
2012 
EHR CLIAC recognizes that serious patient safety risks can arise from errors in 
the order entry, transmission, display and interpretation of laboratory 
data in EHRs. Display and use of non-numerical laboratory information is 
an under-appreciated critical issue. Interoperability with LIS as well as 
correct transmission of data across multiple interfaces is also critical. The 
laboratory community can provide important input and solutions to 
these challenging problems. CLIAC makes the following 
recommendations: 
1. Laboratory experts with experience in hospital, ambulatory or public 
health settings should be members of key ONC advisory committees 
and other agency groups that are setting standards and policies for 
laboratory information in EHRs. 
2. Provider usability is an important strategy for mitigation of these 
patient safety risks. Further work in this area should be supported. 
3. A national system for reporting EHR laboratory related safety events 
and near misses should be established to clearly define the 
prevalence, understand the underlying causes and stimulate the 
design of broad-based solutions. 
4. A catalogue of various solutions for laboratory data should be 
created using work that has already been done and considering areas 
of expertise [e.g., human factors] that may not have been previously 
engaged. 
CLIAC sent a letter (dated September 26, 
2012) to the Secretary, HHS, that included 
this recommendation. HHS reported to 
CLIAC on steps being taken in response to 
the recommendation on August 22, 2013. 




February 14,  
2012 
Cytology 1) CLIAC supports the use of data from operational studies, such as those 
presented to determine if the maximum workload limit using semi-
automated screening instruments is appropriate. To discourage the use 
of maximum workload limits as productivity expectations, CLIAC 
recommends that standardized criteria be developed for use in 
determining workload limits for each individual performing screening. 
 
2) Lowering the workload limits for screening Pap smears using a semi-
automated device may result in improving the quality of testing.  
However, it could also lead to increased turnaround time and costs for 
obtaining test results and could have implications for access to testing. 
CDC, CMS, and FDA developed a study 
plan with input from a cytology 
workgroup. In 2013 CDC funded a contract 
to collect workload data. Project 




CATEGORY CLIAC  RECOMMENDATION STATUS 
August 31-
September 1,  
2011 
Miscellaneous  Implement a work group to outline the scope of issues related to 
communication of laboratory testing information and propose 
approaches to address these issues for discussion by CLIAC. 
The Communication in Informatics 
workgroup met July 11-12, 2012 and 
reported to CLIAC in August 29, 2012. 
Communication issues, in general, 




Cytology  CMS should analyze the cytology proficiency testing data directly in light 
of concerns expressed by the Committee on failure rates, reasons for 
failure, and trends and should present to CLIAC at the next meeting 
along with an analysis of the cytology NPRM and how it addresses these 
concerns.   
At the March 2-3, 2011 CLIAC meeting, 
CMS presented their current data on 
failure trends from 2005-2010 and 









1. Analyte Inclusion/Prioritization and Grading Criteria 
a. There should be a defined list of analytes for which proficiency 
testing (PT) is required.  If legally possible, those analytes should 
be separate from, but linked to, regulations, allowing the list to be 
more flexible.  
b. Inclusion Criteria for determining required PT analytes should be 
scientifically based. 
c. Factors to be considered for adding required PT analytes to 
subpart I of the CLIA regulations should include:  
i. Whether PT exists and material is available 
ii. The volume of testing for an analyte 
iii. Clinical relevance  
iv. Cost of adding an analyte 
d. Criteria used to assess clinical relevance of an analyte should 
include consideration of:  
i. Testing when a treatment decision is made solely on the result 
of that test. 
ii. Tests that have critical values associated, i.e. results that 
require immediate communication with clinicians due to their life-
threatening nature or serious risk to the patient. 
iii. National practice guidelines that include testing the analyte. 
e. There should be a two-year phase in period for implementation of 
required PT after adding analytes to the list. 
f. The required number of PT challenges and frequency (five 
challenges, three times per year) should not be changed. 
g. Ideally every analyte should be assessed with traditional PT.  If PT 
is not available, however, laboratories should continue to use 
alternative proficiency assessment as now required by CLIA. 






Criteria for Acceptable Performance –  
2. Grading criteria should be periodically reviewed for all analytes that 
require PT for continued clinical relevance or when other relevant 
information becomes available. 






Criteria for Acceptable Performance – 
3. Information gathered during the phase-in process for newly required 
PT should be used to scientifically establish grading criteria. 









Criteria for Acceptable Performance –  
4. An indeterminate category should be considered an acceptable 
answer for certain analytes when applicable. 






Criteria for Acceptable Performance –  
5. Peer grouping should be retained when appropriate as a component 
of the grading criteria. 






Criteria for Acceptable Performance –  
6. Definition of the term “Peer Group” for possible inclusion in the 
regulations:  A group of laboratories whose testing process utilizes 
similar instruments, methodologies, and/or reagent systems. 






Criteria for Acceptable Performance –  
7. All vendors involved in the production of PT material need to work 
to minimize matrix effects. 






Criteria for Acceptable Performance –  
8. Designations for PT samples being ungradable (reason codes) should 
be clarified to distinguish between situations when there are too few 
participants to grade and sufficient number of participants but 
consensus is not reached.  






Microbiology PT – 
9. A system for categorizing levels of service must be maintained in the 
regulations to help laboratories determine what PT they need to 
perform and assist surveyors in monitoring PT performance and 
patient testing. 






Microbiology PT – 
10. Laboratories need to declare their patient reporting practices for 
organisms included in each PT challenge.  However, PT programs may 
only gather this information as it is the inspecting agency’s 
responsibility to review and take action if necessary. 






Microbiology PT – 
11. The regulations need to include for all microbiology subspecialties, 
as applicable, stain(s), susceptibility and resistance testing, antigen 
and/or toxin detection, and microbial identification or detection. 






Microbiology PT – 
12. Require PT for a generic list of organisms in each subspecialty.  For 
example, in bacteriology the groups listed should include gram-
negative bacilli, gram-positive bacilli, gram-negative cocci, and gram-
positive cocci. 









Microbiology PT – 
13. For PT, patient histories and source should be provided, however 
this information should not preclude the laboratory from performing 
PT. 






Microbiology PT – 
14. PT results for Gram stains should include both stain reaction and 
morphology. 






Microbiology PT –  
15. Lower the mixed culture requirement from 50% to 25% for PT 
challenges of both sample types (those that require laboratories to 
report only the principal pathogen and those that require 
laboratories to report all organisms present). 






Microbiology PT –  
16. Required PT for antimicrobial susceptibility and/or resistance 
testing should be increased to two challenges per event for a total of 
six challenges per year in bacteriology and should include one gram-
positive and one gram-negative organism in each event. 






 Microbiology PT – 
17. PT should be required for laboratories that perform susceptibility 
and/or resistance testing in all microbiology subspecialties.  It should 
include two challenges per event for a total of six challenges per year 
and should include resistant organisms. 






Microbiology PT – 
18. PT for direct antigen testing should be required for all 
subspecialties. 






Microbiology PT – 
19. Retain the five required challenges per event and 80% required 
consensus for grading. 






Microbiology PT – 
20. All PT programs should be required to provide CMS with the overall 
score for each subspecialty, with a line item underneath that includes 
a score on the individual PT tests or procedures that comprised the 
subspecialty score - such as stain(s), susceptibility and resistance 
testing, antigen and/or toxin detection, and microbial identification 
and detection. 









PT Referral – 
21. Distinguish acceptable “PT referral” from unacceptable PT referral 
with the “intent to defraud” in regulations at §493.801(b)(4) allowing 
CMS more flexibility in imposing sanctions on laboratories. 
CMS addressed PT referral in two rules 
that defined hierarchical actions and 






PT Referral – 
22. Designation of acceptable PT referral would allow laboratories to 
treat PT exactly as patient samples and perform reflex or referral 
testing when it is included in their standard procedure for patients. 
CMS addressed PT referral in two rules 
that defined hierarchical actions and 






PT Referral – 
23. Laboratories should provide documentation to the referral 
laboratory on the nature of the referral.  Referral laboratories should 
not be penalized. 
CMS addressed PT referral in two rules 
that defined hierarchical actions and 




Miscellaneous Create an electronic healthcare record (EHR) workgroup tasked with 
writing a work statement that includes specific issues and 
recommendations for stakeholders to address.  The Committee 
requested updates regarding the progress of the identified issues in 
future meetings. 
The Communication in Informatics 
workgroup met in July 11-12, 2012. 
Updates on EHR implementation have 
been given at CLIAC meetings since 2011. 
February 9-10, 
2010 
Genetic Testing Accept the Biochemical Genetic Testing (BGT) Workgroup report with 
changes as discussed and approved by the Committee. 
Based on CLIAC recommendations, good 
laboratory practices for biochemical 
genetic testing and newborn screening 
were published on April 6, 2012  in the 
Morbidity and Mortality Weekly Report: 
Recommendations and Reports 






Genetic Testing A recommendation was passed stating CLIAC recognizes that there are 
some rare biochemical genetic tests which are needed for patient care, 
but are not currently offered in CLIA-certified laboratories.  CLIAC 
requests that CMS and the Office of Rare Diseases Research at NIH 
identify specific test gaps that exist today and seek support from the 
Office of Rare Diseases Research to set up these tests in CLIA-certified 
laboratories.  This could range from assisting laboratories which 
currently offer these tests to obtain CLIA certification to setting up these 
tests in existing CLIA laboratories. 
With collaboration and input from CDC, 
the NIH office of Rare Disease Research 
established a “Collaboration, Education, 
and Test Translation (CETT)” program 
during 2003-2008 to facilitate 
development of rare disease tests in CLIA-
certified laboratories.   
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
September 2-3, 
2009 
Waived Testing CMS should survey each Certificate of Waiver (CW) laboratory to: 1) 
determine which tests they perform, 2) identify who performs the 
testing, 3) verify that all testing personnel have been trained and shown 
to be competent for each test they perform, and 4) verify that laboratory 
has a copy of the manufacturer's current instructions for the test, and 
that testing personnel follow these instructions when performing 
testing. A pilot study of a subset of CW laboratories should be conducted 
prior to extending the survey to all CW laboratories. 
CMS conducts educational surveys of 2% 
of waived testing sites every year. 
Accreditation agencies also survey some 
waived testing sites. Sufficient resources 
are not available to allow CMS to survey 
all Certificate of Waiver testing sites.  
February 4-5, 
2009 
Miscellaneous Convene a workgroup to identify issues, currently available routes, and 
gaps in translating research testing into CLIA certified clinical 
laboratories. 
CDC convened a workgroup to consider 
next generation sequencing (NGS) and its 
implementation in clinical laboratories. 
CDC established the Next Generation 
Sequencing-Standardization of Clinical 
Testing (Nex-StoCT) Workgroup in April 
2011 to develop guidance for 
implementing NGS into clinical settings.  
The guidelines that resulted from the 
Workgroup deliberations were published 
in Nature Biotechnology in November 
2012 and available at:  
http://www.nature.com/nbt/journal/v30/
n11/full/nbt.2403.html. An update was 
provided to CLIAC on March 2, 2013. 
September 11-12, 
2008 
Waived Testing Conduct a study to gather data about the impact of waived testing on 
patient outcomes, clinician behavior, and other similar issues. 
CDC funded a study "Improved Waived 
Testing Performance and Outcomes 






Establish a workgroup to examine and provide suggestions regarding the 
need for revisions to the CLIA requirements for proficiency testing (PT).  
The PT Workgroup met on March 10, 2010 
and provided input for CLIAC 




CATEGORY CLIAC  RECOMMENDATION STATUS 
September 11-12, 
2008 
Genetic Testing Form a workgroup to consider good laboratory practices for biochemical 
genetic testing (BGT).  
CDC and CMS assembled a workgroup of 
experts to consider good laboratory 
practices for BGT which met June 1-2, 
2009. The workgroup reported to CLIAC on 
February 9-10, 2010 who recommended 
good laboratory practices for biochemical 
genetic testing. These were published on 
April 6, 2012 in the Morbidity and 
Mortality Weekly Report: 
Recommendations and Reports 






Genetic Testing CLIAC provided recommendations on “Good Laboratory Practices for 
Molecular Genetic Testing” and recommended they be published in the 
Morbidity and Mortality Weekly Report: Recommendations and Reports 
(MMWR:R&R).  
Based on CLIAC recommendations, CDC 
published "Good Laboratory Practices for 
Molecular Genetic Testing" was published 
on June 12, 2009 in the Morbidity and 
Mortality Weekly Report: 
Recommendations and Reports 








Considering the Cytology Workgroup's proposals, CLIAC provided 
recommendations for changes to the cytology proficiency testing 
regulations in the following areas: frequency of testing, number of 
challenges, categories of challenges and number of challenges per 
category, grading scheme, retesting, confidentiality, validation, new 
technology, and test site. 
CDC and CMS developed a proposed rule 
for cytology proficiency testing based on 
CLIAC's recommendations.  Proposed rule 
published January 16, 2009. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
February 8-9, 
2006 
Miscellaneous Form a workgroup comprised of epidemiologists, clinical laboratories, 
public health laboratories, industry, and government to examine and 
broadly address issues related to the impact of rapid testing and 
molecular technology on public health. 
A workgroup comprised of stakeholders 
including epidemiologists, clinical labs, 
public health labs, industry and 
government, met on November 2, 2006 to 
consider the impact of rapid and 
molecular tests for infectious disease 
agents on public health. Workgroup 





Convene CLIAC in June 2006 to consider the Cytology Workgroup's 
report and make recommendations for changes to the cytology 
proficiency testing regulations. 
CLIAC met June 20-21, 2006, and provided 
recommendations for revisions to the CLIA 
cytology proficiency testing requirements. 




Miscellaneous Create a laboratory companion document to accompany the CLSI 
document currently under development for manufacturers addressing 
validation of risk mitigation. 
CLSI published a Laboratory Guidance 
Document (EP23); Laboratory Quality 
Control Based on Risk Management. No 





Convene a cytology workgroup to evaluate updated comments from 
professional organizations and the public and address potential changes 
to cytology proficiency testing regulations. 
Cytology Workgroup comprised of 
representatives from professional 
organizations, experts in the field, 
practicing pathologists, and cytologists 
met March 28-29, 2006, to address 
potential changes to cytology proficiency 
testing regulations. The Workgroup 
considered current practices and new 
technology in developing their options for 
regulatory revision, and reported to CLIAC 
on June 20-21, 2006. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
February 16-17, 
2005 
Waived Testing Provide recommendations for good laboratory practices for waived 
testing. 
CLIAC provided recommendations for 
good laboratory practices for waived 
testing which were published 
November 11, 2005, in the Morbidity and 
Mortality Weekly Report: 
Recommendations and Reports 








Consider revising the cytology PT regulations based on updated 
comments from professional organizations and the public to reflect 
current practice, evidence-based guidelines, and anticipated changes in 
technology. 
Discussed at the September 2005 CLIAC 
meeting during which a workgroup 
reported to CLIAC on June 20-21, 2006 
and CLIAC provided recommendations to 
CMS and CDC. Cytology PT proposed rule 
published January 16, 2009. 
September 22-23, 
2004 
Miscellaneous Send letter written by Chair, on behalf of the Committee, to CMS 
supporting continuing the CMS COW surveys beyond 2004. 
Ms. Yost notified the Chair that CMS had 
received funding to continue the COW 
surveys in 2005 and a letter from CLIAC to 
CMS was not needed. 
February 11-12, 
2004 
Waived Testing Convene a workgroup, chaired by Dr. Foucar and Dr. Schwartz, to 
investigate the feasibility and process for publishing CMS waived 
laboratory survey data in CDC's MMWR. 
Workgroup comprised of physicians, 
nurses, laboratorians, manufacturers, 
distributors, and government 
representatives met on January 12, 2004, 
and considered options for publication of 
CMS' waived laboratory survey data and 
best practice guidelines for waived testing. 
Recommendations for good laboratory 
practices for waived testing and CMS 
survey summaries published November 
11, 2005, in  Morbidity and Mortality 
Weekly Report: Recommendations and 
Reports MMWR:R&R, Vol. 54, No. RR-13 





CATEGORY CLIAC  RECOMMENDATION STATUS 
February 11-12, 
2004 
Waived Testing Based on CLIAC Waiver Workgroup Report, the Committee provided 
recommendations for development of criteria and oversight guidelines 
for waived testing to FDA and shared these recommendations with 
AdvaMed. 
Recommendations sent to FDA and 
AdvaMed on April 8, 2004. 
September 17-18, 
2003 
Waived Testing Convene a Waiver Workgroup of key stakeholders, chaired by Dr. 
Goldsmith, to review the testing concerns, data on the process of waiver 
determination and performance of waived tests, and any other relevant 
information; report to CLIAC the Workgroup's recommendations 
regarding appropriate changes to the waiver determination process and 
oversight of waived tests.   
Workgroup comprised of federal agencies, 
industry, laboratorians, physician office 
laboratories, CLIAC, and other 
stakeholders met on January 16, 2004, to 
consider suggestions for changes to the 
waiver determination process and 
oversight of waived tests. Waiver 




Waived Testing Send letter to the Secretary, HHS, expressing the Committee's concerns 
related to the possible waiver of rapid HIV tests from the CLIA 
regulations. CLIAC suggested/recommended the following: (1) 
appropriate oversight, training, QA, QC, and PT are needed for even the 
simplest HIV testing device, (2) careful review of objective evidence of 
test performance by waived testing personnel in waived settings is 
needed before a rapid HIV device is considered for waiver, and (3) the 
limited public health certificate exception under CLIA would allow these 
tests to be used without compromising public health. 




Miscellaneous In response to CAP request, consider letter to Secretary, HHS, regarding 
apparent undue burden of the proposed regulations implementing the 
Health Insurance Portability Accountability Act (HIPAA) on deemed 
laboratory accreditation organizations acting on behalf of CMS, but 
obtain CDC/CMS legal counsel review prior to proceeding.   
Decision made to not send a letter since 
original comment period had closed and 
another HIPAA NPRM was pending 
publication (published March 27, 2002). 
January 30-31, 
2002 
Miscellaneous Include breath, when derived from the human body and tested in a 
laboratory as defined by CLIA, as a specimen source under CLIA.   




Personnel Delete or at least modify the proposed high complexity laboratory 
director qualification requirement at 493.1443(b)(3)(iii) in the 12/28/01 
NPRM to require a more formal mechanism for documenting laboratory 
expertise.   
Deleted in the regulations published in the 
Federal Register on January 24, 2003. 
January 30-31, 
2002 
Waived Testing Readdress CLIAC's June 8, 2001 letter to FDA (providing the Committee's 
recommendations relative to FDA's Draft Waiver Guidance) to the 
Secretary, HHS, as recommendations to be used in rule-making relative 
to the waiver review criteria and processes.  
Letter sent by CLIAC on January 31, 2002. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
January 30-31, 
2002 
Miscellaneous Send letter to Secretary, HHS, expressing CLIAC's support of the National 
Laboratory System.  
Letter sent by CLIAC on April 10, 2002. 
May 30-31, 
2001 
Waived Testing Develop statement reflecting concerns about waiver of rapid human 
immunodeficiency virus tests.   
Statement presented at FDA Blood 





May 30-31,  
2001 
Waived Testing Provide comments to FDA on the Draft Waiver Guidance.  Comments on all aspects of Draft Waiver 
Guidance verbally presented to FDA 
representatives on February 7-8, 2001 and 
May 30, 2001. Letter containing all CLIAC 
comments sent to FDA on June 8, 2001. 
February 7-8, 
2001 
Genetic Testing Accept the Genetic Testing Workgroup's evaluation of comments 
received to the 5/4/00 Notice of Intent (NOI) and include the 
recommendations in a proposed genetic testing rule. 
September 2008 CLIAC meeting: CMS 
determined existing enforcement is 
sufficient and provided an action plan in 
lieu of creating a Genetic Testing specialty. 
February 7-8, 
2001 
Miscellaneous Develop letter expressing CLIAC support for appropriate containment of 
wild poliovirus and the HHS survey to be distributed January 2002 
identifying laboratories that retain wild poliovirus infectious materials, 
and the notification to these laboratories to implement biosafety 
measures.  
Letter sent to Dr. Walter R. Dowdle, 
National Center for Infectious Diseases, 
CDC, February 8, 2001. 
September 27-28, 
2000 
Waived Testing Send letter to Secretary, HHS, requesting opportunity to provide 
comments on waiver process and recommend FDA follow the guidelines 
for waiver approval published in the September 1995 proposed rule. 
Letter sent by CLIAC on September 28, 
2000. 
April 5-6, 2000 Personnel Send letter to Secretary, HHS, regarding crisis caused by laboratory 
workforce shortages.  
Letter sent by CLIAC on May 16, 2000. 
September 22-23, 
1999 
Genetic Testing The Secretary's Advisory Committee on Genetic Testing (SACGT) should 
formally review the CLIAC recommendations for genetic testing in 
making decisions.  
Recommendations were discussed with 
SACGT.  SACGT requested the Asst. 
Secretary for Health to expedite 




Genetic Testing Revise the regulations to add definitions and requirements specific for 
genetic testing for each phase of testing (pre-analytic, analytic, post-
analytic) and globally for all phases, where applicable.   
Published in the Federal Register on May 
4, 2000 as a NOI to solicit comments on 
CLIAC recommendations. 
 
September 2008 CLIAC meeting: CMS 
determined existing enforcement is 
sufficient and provided an action plan in 
lieu of creating a Genetic Testing specialty. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
September 16-17, 
1998 
Miscellaneous Require that embryo laboratory procedures determined to be tests be 
under the purview of CLIA.  
CMS has determined that it will not cover 
embryo lab procedures. Some are strictly 
product evaluation which isn't covered by 
CLIA. Others are clinical and in the scope 
of the practice of medicine and therefore 
not in CLIA. 
August 30-31, 
1995 
Quality Control Revise requirements for certain microbiology reagents to require QC 
testing per lot rather than daily QC testing.  
Included in regulations published in the 
Federal Register on January 24, 2003. 
August 30-31, 
1995 
Quality Control Require laboratories to document the basis on which they establish the 
appropriateness of the quality control limits using acceptable protocols.  
Required in QC regulations. 
August 30-31, 
1995 
Quality Control Include verification of accuracy, precision and reportable range as 
minimum core requirements for method verification for all laboratories.  
Included in regulations published in the 





Lower the consensus required for grading all tests except 
immunohematology, hematology blood cell identification, and 
microbiology organism identification and stain reactions from 90% to 
80% based on the PT providers’ choice of referee laboratories or peer 
groups.  
Included in regulations published in the 
Federal Register on January 24, 2003. 
However, no exceptions were made for 
hematology blood cell identification, 
microbiology organism identification and 





Lower the consensus required for grading microbiology organism 
identification and stain reactions from 90% to 80% based on the results 
of referee laboratories. 
Included in regulations published in the 
Federal Register on January 24, 2003. 
However, consensus required for grading 
was also lowered from 90% to 80% based 
on the results of peer groups.   
DATE 
RECOMMENDED 





Pursue legislative and/or regulatory changes so that cytology proficiency 
testing (PT) applies to laboratories not individuals, evaluate alternative 
media for cytology PT, and encourage development of private and state-
administered glass slide PT programs.  
Statutory revision required to eliminate PT 
of cytology personnel. 
 
Computer-based models have been 
developed and pilot tested through 
cooperative agreements with CDC. 
Screening performance has been 
compared with performance on glass slide 
and computer-based PT programs 
(contract). Study conducted in Maryland 
to compare performance on glass slide 
test to computer-based test performance. 
Publication: Gagnon M, Inhorn S, Hancock 
J, Keller B, Carpenter D, Merlin T, Hearn T, 
Thompson, P and Whalen R. Comparison 
of Cytology Proficiency Testing Glass Slides 
vs. Virtual Slides.  Acta Cytologica vol 48 
No. 6, November-December 2004. 
December 13-14, 
1993 
Miscellaneous Reconsider establishing the accurate and precise technology (APT) 
subcategory of testing, since it may not provide sufficient regulatory 
relief to laboratories; at minimum, publish APT as a proposed rule 
soliciting public comments on the addition of the subcategory and the 
proposed requirements.  
Notice of Proposed Rulemaking (NPRM) 
published in the Federal Register on Sept. 
15, 1995.  NPRM withdrawn in the 
"Unified Agenda of Regulatory and 
Deregulatory Action" published in the 
Federal Register on April 26, 1999. 
December 13-14, 
1993 
Personnel Include doctoral scientists who were board eligible on February 28, 1992 
as personnel qualified to serve as clinical consultants.  
Board eligible candidates as of February 
28, 1992 should have obtained board 
certification. 
August 12,  
1993 
Personnel Do not use board certification as the standard of 
competency/qualification for PPM and do not accept PPM specialty 
subcategories.  
CLIA regulations do not include these 
provisions. 
August 12,  
1993 
Waived Testing Require that all tests, including any cleared by the FDA for home use, 
meet the CDC proposed guidelines for waiver.  
On November 9, 1997, Congress passed 
the FDA Modernization Act which revised 
the CLIA law to require that any test 
approved by the FDA for home use be 
waived under CLIA. As a result, test 
systems cleared by the FDA for home use 
are automatically waived.  
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
August 12,  
1993 
Waived Testing Clarify criteria for waiver (eliminate 'risk of harm' as a criterion for 
waiver, revise criteria to include 'simple laboratory tests and 
examinations which have an insignificant risk of reducing an erroneous 
laboratory test result') and re-evaluate tests currently on the waived list.  
Clarifications to the criteria for waiver and 
proposal to reevaluate currently waived 
tests included in the proposed regulation 
published in the Federal Register on Sept. 
13, 1995. 




Include fecal leukocyte, wet mounts of prostatic secretions, qualitative 
semen analysis in PPM.  
Included in regulations published in the 
Federal Register on April 24, 1995. 
May 26-27,  
1993 
Personnel Clarify bachelor's degree for moderate complexity laboratory director 
and technical consultant and for high complexity general supervisor and 
technical supervisor i.e., define and specify equivalent qualifications for 
the bachelor's degree. 
Requires revisions to the personnel 
regulations. Not on CMS schedule. 
May 26-27,  
1993 
Personnel Revise high complexity testing personnel qualifications to define 
credentials equivalent to an associate degree in medical laboratory 
technology or laboratory science, includes 1 year of laboratory training 
in all laboratory specialties or 3 months in each specialty testing is 
performed.  Also, prohibit labs from hiring high school graduates for high 
complexity testing as of effective date of regulations.  
Included in regulations published in the 
Federal Register on April 24, 1995. 
Note: High school graduates could be 
hired until 8/31/97; however, those hired 
after 1/19/93 require on-site supervision. 
Those hired after 4/24/95 must have 
obtained an associate degree or 
equivalent by 9/1/97. 
May 26-27,  
1993 
Personnel Revise general supervisor requirements to prospectively require a 
bachelor's degree with a 1 year laboratory training component or 3 
months experience in each specialty supervised.  
Requires revisions to the personnel 
regulations. Not on CMS schedule. 
May 26-27,  
1993 
Personnel Do not permit individuals, who qualify as laboratory directors of high 
complexity testing, to qualify as clinical consultants in lieu of other 
requirements.  
No action required (current regulations do 
not include such a provision). 
May 26-27,  
1993 
Personnel Use interpretive guidelines instead of regulations to list various 
qualifications (including physician board certifications) in the personnel 
requirements.  
List of approved certification boards 
removed from the regulations published in 
the Federal Register on January 24, 2003, 
and included in revisions to the SOM 
interpretative guidelines. 
May 26-27,  
1993 
Personnel Qualify respiratory therapists to serve as blood gas general supervisors 
and high complexity testing personnel.  
Requires revisions to the personnel 
regulations. Not on CMS schedule. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
May 26-27,  
1993 
Personnel "Grandfather" individuals serving as a general supervisor on or before 
9/1/92 with: 
-- associate degree in laboratory science, medical technology, or 
equivalent + 2 yrs. exp. 
-- successful completion of accredited laboratory training program or 
military training program + 2 yrs. exp. 
-- High School + documented training + 10 yrs. experience (includes 6 
yrs. supervisory). 
Included in regulations published in the 
Federal Register on April 24, 1995. 
May 26-27,  
1993 
Personnel Qualify neurologists with specialized training and board certification as 
technical supervisors, general supervisors and testing personnel of 
neuromuscular histology.  
The American Academy of Neurology 
Committee for Neuromuscular Pathology's 
documentation of the training and 
qualifications of neurologists has been 
approved as a mechanism to qualify 
neurologists to perform neuromuscular 
examinations and serve as supervisors of 
laboratories performing these 
examinations. 
 
Included in regulations published in the 
Federal Register on January 24, 2003. 
May 26-27,  
1993 
Personnel Qualify individuals with doctoral, master's, bachelor's degrees and 
appropriate experience as technical supervisors of immunohematology.  
Requires revisions to the personnel 
regulations. Not on CMS schedule. 
May 26-27,  
1993 
Personnel "Grandfather" individuals qualified under the March 1990 rule as 
technical supervisors.  
No action required ("grandfather" 
provision for technical supervisor not 
included in 1992 final rule). 
May 26-27,  
1993 
Waived Testing Waive Chemtrak Single Analyte Cholesterol Accumeter.  Categorized as waived, manufacturer 
notified March 17, 1995, included in the 
test categorization notice published in the 
Federal Register on July 8, 1996. 
May 26-27,  
1993 
Personnel Add midlevel practitioners to the individuals qualified to perform PPM 
procedures. Change the name of the PPM subcategory from “physician-
performed" to "provider-performed" microscopy.  
Included in regulations published in the 
Federal Register on April 24, 1995. 
Note: Dentists also added. 
February 17-18,  
1993  
and  




Include examination of nasal smears for granulocytes in PPM.  Included in regulations published in the 
Federal Register on April 24, 1995. 
DATE 
RECOMMENDED 
CATEGORY CLIAC  RECOMMENDATION STATUS 
February 17-18,  
1993 
Personnel Qualify individuals, who as of 9/1/94 are graduates of a laboratory 
training or 50 week military training program, to perform high 
complexity testing without supervisory review. 
Included in regulations published in the 
Federal Register on April 24, 1995. 




Personnel Permit high complexity testing personnel with high school diplomas and 
documented training as of 9/1/92 to continue testing without an 
associate degree indefinitely, provided that testing is reviewed within 24 
hours. 
Included in regulations published in the 
Federal Register on April 24, 1995. 
Note: High school graduates with 
documented training hired prior to 
4/24/95 do not have to obtain an 
associate degree or equivalent.  On-site 
supervision is required for those hired 
between 1/19/93 and 4/24/95. 
February 17-18, 
1993 
Waived Testing Do not add rapid strep test to the list of waived tests. Several rapid strep tests have met the 
CLIA requirements for waiver and are 
categorized as waived. The list of tests 
waived may be accessed via Internet at:  
http://www.accessdata.fda.gov/scripts/cd





Do not include Gram stain, Tzanck test and rapid strep tests in PPM.  No action required. These procedures do 
not meet the criteria for categorization as 
a PPM procedure. 
February 17-18, 
1993 
Waived Testing Develop definitive criteria for categorizing tests as waived and declare a 
moratorium on further review of tests for waived status until the 
definitive criteria are developed. 
Declared a moratorium on waiver 
determinations.  Moratorium lifted in 
December 1994 when draft guidelines 
containing clarified waiver criteria and 
process for reviewing waiver requests 
issued to all manufacturers of moderate 





Recategorize the HDL-cholesterol performed on the Kodak Ektachem DT 
60 from high to moderate complexity and have the Kodak Ektachem DT 
60 serve as an Aindex@ test system for the review of similar HDL 
cholesterol test systems. 
Included in the test categorization notice 




Waived Testing Add Hemocue hemoglobin testing to the list of waived tests.  Added "hemoglobin by single analyte 
instrument…" to the waived test list in 
regulations published in the Federal 
Register on January 19, 1993. 
DATE 
RECOMMENDED 





Categorize urethral/cervical Gram stains as moderate complexity.  
Categorize Gram stains from all other sources as high complexity.  
Included in the test categorization notice 






Consider the isolation, identification, and susceptibility of organisms 
transferred from culture as a single test and categorize as high 
complexity.  
Included in the test categorization notice 




Miscellaneous Create a subcategory of moderate complexity, physician-performed 
microscopy procedures (PPM) that does not require routine inspections.  
Include wet prep, KOH prep, post-coital exam, Fern test, pinworm test 
and urine microscopic exams in PPM.  
Included in regulations published in the 
Federal Register on January 19, 1993. 
 
